DoW Neurofibromatosis Exploration-Hypothesis Development Award

The Neurofibromatosis Exploration-Hypothesis Development Award is offered through the Department of Defense under the Defense Health Agency Contracting Activity as part of the broader Neurofibromatosis Research Program. This federal funding initiative is designed to support early-stage, high-risk, high-reward scientific research that has the potential to significantly advance understanding of neurofibromatosis. The program reflects the Department of Defense’s commitment to improving health outcomes for individuals affected by this group of genetic disorders, which can cause tumors to form on nerve tissue and lead to a range of serious complications. The primary objective of this award mechanism is to encourage the development and initial testing of innovative hypotheses that may open new directions in neurofibromatosis research. Projects funded under this opportunity are expected to explore novel concepts that challenge existing scientific paradigms or approach known problems from entirely new perspectives. While preliminary or published data may strengthen an application, such data is not required, which lowers the barrier to entry for groundbreaking but unproven ideas. The emphasis is on creativity, scientific rationale, and the potential for transformative impact. Funding provided through this opportunity is intended to support research activities that establish foundational knowledge and generate preliminary findings for future, more extensive investigations. Although specific award ceilings and floors are not defined in the available information, the total estimated program funding is 1,280,000 dollars, with approximately eight awards expected. Funds may be used to support research personnel, supplies, and other project-related expenses consistent with federal grant regulations. There is no cost sharing or matching requirement, allowing applicants to focus fully on the proposed research without the need to secure additional financial contributions. Eligibility for this funding opportunity is described as unrestricted, meaning that a wide range of entities may apply, subject to any additional clarifications in the full announcement. This inclusive approach typically encompasses academic institutions, nonprofit organizations, private sector entities, and potentially individuals, provided they meet the criteria outlined in the official solicitation. Applicants are expected to submit proposals that clearly articulate a testable hypothesis, supported by a strong scientific rationale and a well-designed study plan. The application process is conducted through established federal grant submission systems, with applicants required to prepare and submit a complete proposal package by the stated deadline. While specific application components are not detailed in the summary, standard federal research grant submissions generally include a project narrative, budget justification, and supporting documentation. Applicants may need to engage with electronic systems such as eBRAP for registration and submission support. Technical assistance is available through the eBRAP Help Desk, which can be contacted via email or phone for issues related to accessing or submitting the application. Applications are currently open, with a posted date of June 25, 2026, and a final submission deadline of September 22, 2026. No pre-application requirements such as letters of intent are specified in the available summary. The opportunity does not explicitly state whether it recurs annually, but it is associated with a fiscal year program, suggesting the possibility of future cycles. Award decisions and project timelines are not detailed in the summary, but funded projects are expected to contribute to the advancement of neurofibromatosis research and lay the groundwork for subsequent studies.

Emphasize innovative high risk high reward concepts and clearly articulate a strong testable hypothesis supported by scientific rationale